Tag: CXCR4

Lipid nanoparticles-based therapy in liver metastasis

Key Points Liver metastasis, which is highly prevalent in advanced malignancies, was associated with poor prognosis. Contemporary therapies in liver metastasis were associated with the lack of metastatic-targeting ability, significant systemic toxicities and incapability of tumor microenvironment (TME) modulations. Lipid nanoparticles (LNP)-based strategies would overcome the deficiencies of conventional approaches…

Continue Reading Lipid nanoparticles-based therapy in liver metastasis

Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

Introduction Human immunodeficiency virus (HIV) infection is associated with an increased risk of hematological malignancy. Lymphoid neoplasms, particularly non-Hodgkin lymphoma, are the main hematologic malignancies that occur more frequently in connection with HIV infection non-Hodgkin lymphoma (NHL).1 Lymphomas are neoplastic lesions of the lymphoid system. According to World Health Organization…

Continue Reading Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM)  Rapidly Advancing U.S. Commercial Activities in Support of Potential September Launch  Announced Publication in Nature Medicine of GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and…

Continue Reading BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Screening and verification of key ubiquitination genes

Introduction Liver cancer is the third most common cause of cancer death globally with hepatocellular carcinoma (HCC) accounting for the majority of liver cancer.1,2 Early HCC (stage I/II) treatment mainly includes radical surgical resection, radiofrequency ablation and liver transplantation.3,4 However, there is a lack of typical clinical symptoms with early-stage…

Continue Reading Screening and verification of key ubiquitination genes

X4 Pharmaceuticals Announces Positive Phase 3 Results

~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75% reduction in the percentage of individuals experiencing severe infections (Grade 3 or higher) in the mavorixafor group vs. placebo group >70% reduction in mean total days with infections (2 weeks on mavorixafor treatment vs. 7…

Continue Reading X4 Pharmaceuticals Announces Positive Phase 3 Results

Influence of corticosteroid treatment on CXCR4 expression in DLBCL

Background: CXCR4-targeted radioligand therapy (RLT) with [177Lu]Lu/[90Y]Y-PentixaTher has recently evolved as a promising therapeutic option for patients with advanced hematological cancers. Given their advanced disease stage, most patients scheduled for PentixaTher RLT require concomitant or bridging chemotherapy to prevent intermittent tumor progression. These (mostly combination) therapies may cause significant downregulation…

Continue Reading Influence of corticosteroid treatment on CXCR4 expression in DLBCL

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update Company to host webinar event on May 16 th presenting new clinical data from the 4WHIM Phase 3 trial; oral presentation to follow on May 21 st at the 2023 Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission…

Continue Reading X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports First-Quarter 2023 Financial

Company to host webinar event on May 16th presenting new clinical data from the4WHIM Phase 3 trial; oral presentation to follow on May 21st at the 2023Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission of mavorixafor for WHIM syndrome on track for early 2H 2023 Presentation of data from…

Continue Reading X4 Pharmaceuticals Reports First-Quarter 2023 Financial

Uproleselan Combinations Contribute to Robust Investigational Profile in AML

Michael Andreeff, MD, PhD The E-selectin inhibitor uproleselan (GMI-1271) has shown preliminary efficacy in patients with acute myeloid leukemia (AML), and E-selectin could represent one of several novel targets for treatment of this patient population, according to Michael Andreeff, MD, PhD. Previously, a phase 1/2 trial (NCT02306291) investigating uproleselan plus…

Continue Reading Uproleselan Combinations Contribute to Robust Investigational Profile in AML

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020). CAS  PubMed  PubMed Central  Google Scholar  Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017). CAS  PubMed  PubMed…

Continue Reading Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Immune cell dynamics deconvoluted by single-cell RNA sequencing in normothermic machine perfusion of the liver

Study cohort and performance during NMP An overview of the overall study population is presented in Table 1 (individual data are given in Supplementary Table 1). Detailed information on study livers and analysis is provided as workflow scheme in Fig. 1. The decision to apply NMP was based on one or a combination…

Continue Reading Immune cell dynamics deconvoluted by single-cell RNA sequencing in normothermic machine perfusion of the liver

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma – BioLine Rx (NASDAQ:BLRX)

– GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints – – Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population undergoing autologous HSCT, including older patients and those who received lenalidomide-containing induction therapies – factors associated with impaired HSPC mobilization…

Continue Reading BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma – BioLine Rx (NASDAQ:BLRX)

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Patient demographics were comparable across study cohorts From 22 January 2018 to 30 October 2020, a total of 122 patients from 18 sites in five countries were enrolled and randomized 2:1 to receive either motixafortide + G-CSF (80 patients) or placebo + G-CSF (42 patients) for HSPC mobilization (Fig. 1 and Extended Data Fig. 1a). Demographics between the two treatment…

Continue Reading Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Cancer: Enhancing stem-cell mobilization for transplantation in multiple myeloma | Nature Medicine

A new compound, motixafortide, can safely mobilize an optimal number of stem cells for collection and transplantation in over 90% of 80 patients with multiple myeloma (a cancer of the bone marrow) with 1 injection, reports a phase 3 clinical trial published in Nature Medicine. This approach could improve treatment…

Continue Reading Cancer: Enhancing stem-cell mobilization for transplantation in multiple myeloma | Nature Medicine

Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis

Design and synthesis of indolyl pyrimidinamine inhibitors of TTBK1/2 Our lead (AMG28, Fig. 1A) emerged from examination of the off-target activity of a published Amgen NF-κB inducing kinase (NIK) inhibitor27. The potency of AMG28 was reported in the MRC Kinase Profiling Inhibitor Database as 8% activity remaining for TTBK1 and 12%…

Continue Reading Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis

HSPCs and off-target effects of CRISPR-Cas9

Sponsored Content by MaxCyte, Inc.Apr 13 2023Reviewed by Maria Osipova Efficient and reliable delivery of DNA, mRNA, and Ribonucleoprotein (RNP)-based reagents into primary and stem cells is imperative for precision genome engineering. For clinical gene editing, a transfection platform that does not compromise genome stability and cell viability, is required. The…

Continue Reading HSPCs and off-target effects of CRISPR-Cas9

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM

X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of…

Continue Reading X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) – X4 Pharmaceuticals (NASDAQ:XFOR)

X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. XFOR, a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the…

Continue Reading X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) – X4 Pharmaceuticals (NASDAQ:XFOR)

Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs

Cell culture We cultured mESCs in t2iL medium containing Dulbecco’s modified eagle medium (DMEM, Nacalai Tesque), 2 mM Glutamax (Nacalai Tesque), 1× non-essential amino acids (Nacalai Tesque), 1 mM sodium pyruvate (Nacalai Tesque), 100 U ml−1 penicillin, 100 μg ml−1 streptomycin (P/S) (Nacalai Tesque), 0.1 mM 2-mercaptoethanol (Sigma) and 15% fetal bovine serum (FBS) (Gibco), supplemented with…

Continue Reading Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs

Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival

Introduction Colorectal cancer (CRC) is a leading cause of cancer-related death1 and its mortality rate is expected to rise worldwide, due to population growth and aging, thus entailing a global public health challenge. CRC mortality is mainly due to therapy resistance and metastasis, which are driven by a small population…

Continue Reading Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival

Alzheimer’s Gene MS4A4A Governs the State of Microglia

03 Mar 2023 Of the dozens of loci genome-wide association studies have linked to Alzheimer’s, most are mysterious to scientists. How do they contribute to disease? Much work focuses on changes in expression of individual genes, but as reported in a preprint posted to medRxiv on February 8, scientists led…

Continue Reading Alzheimer’s Gene MS4A4A Governs the State of Microglia

CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death

Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–91. Article  CAS  PubMed  Google Scholar  Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity…

Continue Reading CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death

Beyond Biotech podcast 34

This week, our guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics. GPCR Therapeutics launches multiple myeloma trial  GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR)…

Continue Reading Beyond Biotech podcast 34

Antineoplastic effect of therapeutic nanoparticles targeted to CXCR4+ diffuse large b-cell lymphoma cells

Nowadays, novel therapeutic strategies are urgently needed to reduce relapse rates after R-CHOP treatment and to enhance the survival of diffuse large B-cell lymphoma (DLBCL) patients. Selective delivery of antineoplastic agents to cancer cells, using actively-targeted nanoparticles, is a novel approach that promises to revolutionize therapy by dramatically increasing the…

Continue Reading Antineoplastic effect of therapeutic nanoparticles targeted to CXCR4+ diffuse large b-cell lymphoma cells

SLC7A11 is a prognostic biomarker in UCEC

Introduction Endometrial cancer (EC) is one of the most frequently diagnosed types of gynecological cancers, second only to cervical cancer in incidence.1 More than 50,000 women die from EC worldwide each year.2 Despite the development of diagnostic techniques and treatment means, the prognosis of advanced EC remains unsatisfactory.3,4 The therapeutic…

Continue Reading SLC7A11 is a prognostic biomarker in UCEC

Generation of mesenchymal stromal cells from urine-derived iPSCs of pediatric brain tumor patients

Introduction In 2006, there was a breakthrough in the field of regenerative medicine, when Takahashi and Yamanaka developed the technology to transform any somatic cell into a pluripotent stem cell. These reprogrammed cells, called induced Pluripotent Stem Cells (iPSCs), can be generated by ectopic expression of four transcription factors (i.e….

Continue Reading Generation of mesenchymal stromal cells from urine-derived iPSCs of pediatric brain tumor patients

Download “Epigenetic Memory” Phenomenon in Induced Pluripotent Stem Cells. PDF

reVIeWS “Epigenetic Memory” Phenomenon in Induced Pluripotent Stem Cells E.A. Vaskova1,2,3, A.E. Stekleneva1,2,3, S.P. Medvedev1,2,3, S.M. Zakian1,2,3,* 1Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, prosp. Akad. Lavrentyeva, 10, Novosibirsk, Russia, 630090 2Meshalkin State Research Institute of Circulation Pathology, Rechkunovskaya Str., 15, Novosibirsk, Russia, 630055 3Institute of…

Continue Reading Download “Epigenetic Memory” Phenomenon in Induced Pluripotent Stem Cells. PDF

dot-lot code issue

pdf(file=”celltype_markergene_dotplot.pdf”,width=20) DotPlot(data, features =c(“DCN”, “COL1A2”, “CFD”, “KLRB1”, “CD7”, “GZMK”, “MT1G”, “MT1H”, “MT1F”, “HSPA1A”, “HSPA6”, “DNAJB1”, “CCL5”, “CD3E”, “CXCR4”, “IFI27”, “TM4SF1”, “CLDN5”, “HLA-DRA”, “HLA-DPB1”, “HLA-DQB1”, “S100A9”, “S100A8”, “LST1”, “GNLY”, “GZMB”, “FGFBP2”, “S100A2”, “SFN”, “KRT14”, “CCL4”, “CCL3”, “NKG7”, “ALDOB”, “PCK1”, “MT1G”, “S100A8”, “S100A9”, “FCGR3B”, “PRSS1”, “CLPS”, “PNLIP”, “SFTPC”, “CXCL2”, “SFTPA1”, “HSPA6”, “HSPA1A”,…

Continue Reading dot-lot code issue

Evasion of cGAS and TRIM5 defines pandemic HIV

Cells and reagents HEK293T and U87 cells were maintained in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Labtech) and 100 U ml−1 penicillin plus 100 μg ml−1 streptomycin (Pen/Strep; Gibco). THP-1-IFIT1 cells that had been modified to express Gaussia luciferase under the control of the IFIT1 promoter were described previously62. THP-1…

Continue Reading Evasion of cGAS and TRIM5 defines pandemic HIV

BTG2 gene predicts poor outcome in PT-DLBCL

Introduction Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive form of mature B-cell lymphoma.1–3 PT-DLBCL was the most common type of testicular tumor in men aged over 60 and characterized by painless uni- or bilateral testicular masses with infrequent constitutional symptoms.4–6 PT-DLBCL shows significant extranodal tropism,…

Continue Reading BTG2 gene predicts poor outcome in PT-DLBCL

Identification of Hub Genes Associated with COPD Through Integrated Bi

Introduction Chronic obstructive pulmonary disease (COPD) will become the third leading cause of death worldwide.1,2 The incidence of COPD worldwide is 13.1%3 and is 13.7% in the Chinese population over 40 years of age.4 Emphysema is one of the most common phenotypes.1 Over the past few decades, we have conducted…

Continue Reading Identification of Hub Genes Associated with COPD Through Integrated Bi

Identification of differentially expressed genes in AF

Defeng Pan,1,&ast; Yufei Zhou,2,&ast; Shengjue Xiao,1,&ast; Yue Hu,3,&ast; Chunyan Huan,1 Qi Wu,1 Xiaotong Wang,1 Qinyuan Pan,1 Jie Liu,1 Hong Zhu1 1Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People’s Republic of China; 2Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of…

Continue Reading Identification of differentially expressed genes in AF

Crosstalk between Venous Thromboembolism and Periodontal Diseases: A Bioinformatics Analysis

This article was originally published here Dis Markers. 2021 Dec 10;2021:1776567. doi: 10.1155/2021/1776567. eCollection 2021. ABSTRACT BACKGROUND: This current study applied bioinformatics analysis to reveal the crosstalk between venous thromboembolism (VTE) and periodontitis, as well as the potential role of immune-related genes in this context. METHODS: Expression data were downloaded…

Continue Reading Crosstalk between Venous Thromboembolism and Periodontal Diseases: A Bioinformatics Analysis

r – Error in colSums(mat) : ‘x’ must be numeric GOchord plot

I was trying to plot the gene chord diagram, but I got an error” Error in colSums(mat) : ‘x’ must be numeric”. I prepared the file myself, I submitted the target genes on Metascape, all these genes were enriched and picked from 6 signal pathways clusters. And then I downloaded…

Continue Reading r – Error in colSums(mat) : ‘x’ must be numeric GOchord plot

Establishment of sunitinib-resistant CDX model of ccRCC

Introduction Renal cell carcinoma (RCC) accounts for approximately 2–3% of all malignant tumors, and its prevalence is rising. Metastatic RCC accounts for 25–30% of all RCC cases, and has an exceedingly poor prognosis.1 In 2020, among approximately 430,000 newly discovered cases of RCC, 179,000 died.2 Clear cell renal cell carcinoma…

Continue Reading Establishment of sunitinib-resistant CDX model of ccRCC

Gene expression profiling of contralateral dorsal root gangl

Introduction Mirror-image pain (MIP) is a mysterious pain phenomenon which is accompanied with many clinical pain conditions.1 MIP develops from the healthy body region which is contralateral to the actual injured site.1–3 MIP is typically characterized by increased mechanical hypersensitivity on the uninjured mirror-image body side.4 It can be triggered…

Continue Reading Gene expression profiling of contralateral dorsal root gangl

CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

This article was originally published here Cancer Gene Ther. 2021 Sep 1. doi: 10.1038/s41417-021-00365-x. Online ahead of print. ABSTRACT The highly restricted expression of B-cell maturation antigen (BCMA) on plasma cells makes it an ideal target for chimeric antigen receptor (CAR) immune cell therapy against multiple myeloma (MM), a bone…

Continue Reading CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model